What is the recommended antimicrobial therapy for Acinetobacter baumannii infections based on susceptibility patterns?

Treatment of Acinetobacter baumannii Infections

For carbapenem-susceptible A. baumannii in areas with low carbapenem resistance, carbapenems (imipenem 0.5-1 g every 6 hours or meropenem 2 g every 8 hours) are the drugs of choice; for carbapenem-resistant A. baumannii (CRAB), use polymyxin-based combination therapy with at least two active agents, prioritizing sulbactam/durlobactam when available. 1

Empirical Coverage Decision Algorithm

Empirical coverage for A. baumannii is warranted in these specific scenarios 1:

• Active A. baumannii outbreak in your facility
• Endemic A. baumannii situation with high local prevalence
• Patient previously colonized with A. baumannii (especially if carbapenem-resistant)
• ICU patients with multiple risk factors: prior colonization, immunosuppression, prolonged mechanical ventilation, previous carbapenem or 3rd generation cephalosporin use, central lines, nasogastric tubes, or long ICU stays

Critical pitfall: Do NOT provide empirical A. baumannii coverage routinely—this drives resistance and exposes patients to unnecessary polymyxin toxicity. Reserve it for the high-risk scenarios above.

Treatment Based on Susceptibility Patterns

Carbapenem-Susceptible A. baumannii (Low Local Resistance Areas)

Use carbapenems as monotherapy 1:

• Imipenem: 0.5-1 g IV every 6 hours (cannot use extended infusion due to drug instability)
• Meropenem: 2 g IV every 8 hours (caution: high doses associated with seizures)
• Note: Ertapenem lacks activity against A. baumannii—never use it

Carbapenem-Resistant A. baumannii (CRAB)

Combination therapy with at least 2 active agents is recommended for severe infections 2, 3. The evidence base is nuanced:

First-Line Options:

Polymyxin-based regimens (polymyxins have the greatest in vitro activity against CRAB) 1:

• Colistin (Polymyxin E):

  • Loading dose: 6-9 million IU
  • Maintenance: 9 million IU/day in 2-3 divided doses
  • Note: 1 million IU = 80 mg colistimethate sodium (CMS)

• Polymyxin B:

  • Loading dose: 2-2.5 mg/kg
  • Maintenance: 1.5-3 mg/kg/day in 2 doses
  • Can use continuous infusion; same dose for CRRT patients

Important evidence consideration: The AIDA and OVERCOME randomized trials showed no mortality benefit for colistin-carbapenem combinations over colistin monotherapy in CRAB infections 2. However, combination therapy is still recommended to prevent resistance emergence and because A. baumannii typically has very high carbapenem MICs (>16 mg/L) when resistant.

Sulbactam as Alternative/Combination Agent:

Sulbactam has intrinsic activity against A. baumannii and may be preferable to polymyxins when susceptible (MIC ≤4 mg/L) due to better safety profile 1:

• Dose: 9-12 g/day in 3-4 divided doses (as ampicillin-sulbactam)
• Administration: 4-hour infusion recommended for optimal PK/PD
• Evidence: Studies showed ampicillin-sulbactam had comparable efficacy to colistin but with significantly lower nephrotoxicity (15.3% vs 33%) and lower 30-day mortality in some retrospective studies 1

Critical caveat: Do NOT use sulbactam or tigecycline as monotherapy for empirical therapy 1. Only use for directed therapy when susceptibility confirmed.

Novel Agents (When Available):

• Sulbactam/durlobactam: Prioritized by IDSA guidelines as core treatment for CRAB when available 3
• Cefiderocol: Consider for refractory infections or prior treatment failures, though mortality data from trials are inconsistent 3

Other Combination Options:

• Tigecycline:

  • Standard dose: 100 mg loading, then 50 mg IV every 12 hours (for approved indications like abdominal infections)
  • High dose: 200 mg loading, then 100 mg IV every 12 hours (for pneumonia/primary bacteremia—off-label, always combine with another active agent) 1

• Rifampin: 600 mg/day or 600 mg every 12 hours—always in combination, though RCTs showed no mortality benefit for colistin-rifampin over colistin alone 2

• Fosfomycin: 12-24 g/day in 3-4 doses—always in combination 1

Evidence conflict to note: While the 2015 ICU task force guidelines support combination therapy [1-1], the 2022 ESCMID guidelines 2 provide high-certainty evidence AGAINST carbapenem-polymyxin combinations based on the AIDA and OVERCOME trials. However, both agree on using combinations for severe infections—the debate is which specific combinations.

Resistance Patterns to Consider

Recent surveillance data shows 4, 5, 6:

• Carbapenem resistance: 62-90% globally (meropenem 66.4%, imipenem 62.6%)
• Fluoroquinolone resistance: >70% (ciprofloxacin 71.8%)
• Colistin susceptibility: Maintained at ~93% globally
• Minocycline: 69% susceptible globally, but >90% in Americas
• Amikacin: Shows relatively better activity but modest discriminatory performance

OXA-23 and OXA-72 carbapenemases are the predominant resistance mechanisms globally 6.

Key Clinical Pitfalls

1. Don't use carbapenems as monotherapy in high-resistance areas—you're setting up for treatment failure 1

2. Polymyxin nephrotoxicity is real—colistin causes renal impairment in 33% of patients; consider sulbactam when MIC ≤4 mg/L 1

3. Susceptibility testing for sulbactam is unreliable with automated methods—use E-test with MIC ≤4 mg/L as susceptibility cutoff 1

4. High-dose meropenem (2 g every 8 hours) increases seizure risk—monitor neurological status 1

5. Colistin-rifampin combinations showed no mortality benefit in powered RCTs—don't rely on this combination 2